Home › Schizophrenia › Illinois
Schizophrenia clinical trials in Illinois
25 studies for Schizophrenia are looking for participants at sites in Illinois.
Cities in Illinois
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
- Local Institution - 0067, Chicago
- Pillar Clinical Research -Chicago, Chicago
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 28, 2026 · NCT07686263A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
- Uptown Research Institute, Chicago
RecruitingPhase 1
Ages 18 to 55 · All sexes · Updated Sep 28, 2026 · NCT07615426NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
- Neurocrine Clinical Site, Chicago
- Neurocrine Clinical Site, Oak Brook
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 25, 2026 · NCT07114874Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
- Baber Research Group, Naperville
RecruitingPhase 3
Ages 5 to 17 · All sexes · Updated Sep 25, 2026 · NCT06229210A Study of Brenipatide in Adult Participants With Schizophrenia
- Re:Cognition Health - Chicago, Chicago
RecruitingPhase 2
Ages 18 to 55 · All sexes · Updated Sep 22, 2026 · NCT07410507A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
- Local Institution - 0175, Chicago
- EmVenio Research Center - Prime Healthcare, Chicago
RecruitingPhase 3
Ages 5 to 17 · All sexes · Updated Sep 22, 2026 · NCT07424404A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Naperville
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT0710511152-week Open Label Safety-Tolerability Study
- Pillar Clinical Research, Chicago
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 9, 2026 · NCT07369154A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
- Local Institution - 0122, Chicago
- EmVenio Research Center - Prime Healthcare, Chicago
RecruitingPhase 3
Ages 13 to 17 · All sexes · Updated Sep 4, 2026 · NCT07288567A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
- Uptown Research Institute, Chicago
RecruitingPhase 1
Ages 18 to 55 · All sexes · Updated Sep 2, 2026 · NCT07061288A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
- Clinical Site, Chicago
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Sep 1, 2026 · NCT07459647Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
- Evanston Hospital, Evanston
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT07101094Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
- Local Institution - 0046, Crystal Lake
- Amr Conventions Research - Illinois, Warrenville
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT07379827Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
- Alkermes Investigator Site, Chicago
RecruitingPhase 3
Ages 10 to 17 · All sexes · Updated Aug 14, 2026 · NCT05303064Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
- Uptown Research Institute LLC, Chicago
- Pillar Clinical Research LLC, Chicago
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Jul 29, 2026 · NCT07467993Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
- Pillar Clinical Research, Chicago
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Jul 27, 2026 · NCT07363577Transition Care for FEP
- University of Chicago Ingalls Memorial Hospital, Harvey
RecruitingObservational study
Ages 18 to 40 · All sexes · Updated Jul 20, 2026 · NCT07713849A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
- Uptown Research Institute, Chicago
RecruitingPhase 2
Ages 18 to 55 · All sexes · Updated Jun 23, 2026 · NCT07191483A Study to Evaluate the Effect of KarXT on Urological Safety
- Uptown Research Institute, Chicago
- Pillar Clinical Research -Chicago, Chicago
RecruitingPhase 4
Ages 18 to 65 · All sexes · Updated Jun 3, 2026 · NCT07221877CLOZAPINE Response in Biotype-1
- University of Chicago, Chicago
RecruitingPhase 4
Ages 18 to 60 · All sexes · Updated May 11, 2026 · NCT04580134Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
- University of Chicago Medical Center, Chicago
RecruitingObservational study
Ages 18 to 40 · All sexes · Updated Mar 10, 2026 · NCT06740383NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- Neurocrine Clinical Site, Chicago
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Mar 6, 2026 · NCT06963034Randomized Withdrawal Study in Patients With Schizophrenia
- Vanda Investigational Site, Chicago
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Jan 12, 2026 · NCT06961968Study of ALTO-101 in Patients With Schizophrenia
- Site 5056, Chicago
RecruitingPhase 2
Ages 21 to 55 · All sexes · Updated Dec 26, 2025 · NCT06502964Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
- Reviva site, Chicago
RecruitingPhase 3Healthy volunteers welcome
Ages 18 to 65 · All sexes · Updated Dec 19, 2024 · NCT05184335From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.